We describe a series of 102 patients diagnosed from January 1, 1990 to December 31, 2015 with Type 1 monoclonal cryoglobulinemia (MoC). Symptoms were seen in 89 (87%) patients, including: cutaneous symptoms in 64 (63%) patients, with purpura (n 5 43, 42%) and ulcers/gangrene (n 5 35, 34%) being most common; neurological findings in 33 (32%) patients, most frequently sensory neuropathy (n 5 24, 24%); vasomotor symptoms, mainly Raynaud's phenomenon in 25 (25%); arthralgias in 24 (24%); and renal manifestations, primarily glomerulonephritis in 14 (14%) patients. An underlying lymphoproliferative disorder was identified in 94 (92%) subjects; MGUS-39, myeloma-20, lymphoplasmacytic lymphoma-21 and others-14. Treatment was initiated in 73 (72%) patients, primarily for cryoglobulinemia-related symptoms in 57. Treatment regimens consisted of: steroids 6 alkylating agents in 29 (40%), novel myeloma therapies in 16 (22%), rituximab with alkylating agents in 12 (16%) and rituximab 6 steroids in 11 (15%) patients; 22 patients received plasmapheresis. Six patients underwent autologous stem cell transplant. Cryocrit at treatment initiation, change in cryocrit and time to nadir cryocrit were predictive of symptom improvement. Treatment directed toward the underlying clonal disorder resulted in improvement (n 5 47) or stabilization (n 5 16) of symptoms in the majority of patients and disappearance of cryoglobulin in over one-half.
with cryoglobulinemia. Electronic Health Record (EHR) of these patients was reviewed to identify patients with Type 1 MoC as evidenced by isolation of type 1 cryoglobulin in serum and/or biopsy.
Clinical and laboratory data as well as treatment details and outcomes were extracted from the records.
| Cryoglobulin detection
Cryoglobulin detection is performed by collection of the specimen, which is initially kept at 378 C until separation of serum and plasma, and is then placed in a refrigerator at 28C-68C for 24 hours. If a precipitate develops in the serum, the specimen is centrifuged and the percent precipitate is reported. Negative specimens are kept at 28C-68C for 7 days and rechecked visually. All positive cryoglobulins are analyzed by immunofixation (IFE) to determine if the precipitate is a monoclonal protein, polyclonal protein, or a mixed cryoglobulin.
| Clinical presentation
Symptoms related to cryoglobulins were categorized as follows: skin manifestations (ulcers or gangrene, livedo reticularis, purpuric rash and others); vasomotor symptoms (Raynaud's phenomenon and acrocyanosis); neurological symptoms (peripheral neuropathy attributable to cryoglobulinemia, which could be sensory, motor or mixed and CNS manifestations); musculoskeletal symptoms (arthralgias); renal involvement (renal function impairment and proteinuria) and other symptoms related to cryoglobulins.
| Treatment and disease assessments
Treatment regimens and reason for initiating treatment (i.e. primarily for symptoms related to Type 1 MoC or for the underlying lymphoproliferative disorder) were recorded. Response of symptoms with treatment as well as objective response of the underlying lymphoproliferative disorder was evaluated. The reasons for stopping treatment, as well as the outcome following discontinuation of therapy were also recorded. Response assessment in patients with multiple myeloma and Waldenstrom's macroglobulinemia was done utilizing international consensus criteria for response. 8, 9 Treatment was broadly divided into the following categories: steroids alone; steroids in combination with alkylating agents; rituximab with or without steroids; rituximab and alkylating agents with or without steroids; novel myeloma drugs including immunomodulatory drugs (IMiDs) and proteasome inhibitors; and "other" therapies including anti-metabolites like azathioprine and methotrexate. Treatment with plasmapheresis and autologous stem cell transplant was also reviewed. Response in symptoms was characterized as complete (all involved organs showed improvement), partial (improvement only seen in some symptoms) and no response (none of the symptoms improved).
| Statistical analysis
Statistical Analysis was done using JMP software (JMP®, Version 10. (54%) were male and 97 (95%) were Caucasian. The median cryocrit at diagnosis was 7.5% (n 5 81). A detectable heavy chain was seen in 90 patients, with IgG being the most common (53%, n 5 50) followed by IgM (39%, n 5 37) and biclonal IgG and IgM (5%, n 5 5). In patients with hepatitis C, median hepatitis C virus levels by PCR were 661 975 IU/ml (range 10 800-1 028 571). These patients did not have known underlying mixed cryoglobulinemia.
SAS Institute Inc

| Underlying disorder
| Clinical presentation
Clinical symptoms were present in 89 (87%) patients at diagnosis (Table   1 ). In the remaining, cryoglobulins were checked during diagnostic evaluation for various symptoms, which were ultimately found to be unrelated. Sixty four (63%) patients had skin manifestations, with purpura SIDANA ET AL. However, the median number of symptom groups at presentation was two and it was rare to have patients with symptoms of more than three symptom groups (6%). It was unusual to see arthralgias as the only manifestation (n 5 2) and atypical symptoms in isolation were seen in only one patient, who presented with MGUS related xanthomas, which worsened with cold. performance status led to treatment discontinuation. First-line therapy was still being continued in four (6%) patients at the time of last assessment and reasons for treatment discontinuation were not known in four (6%) patients.
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| Treatment
| Cryocrit
Median cryocrit at diagnosis was 7.5% (range 0-96; n 5 81); 3.3% in patients (n 5 13) who did not have symptoms compared to 9% in those (n 5 68) who presented with symptoms relating to the cryoglobulins (P 5 .26). Patients with associated hematologic malignancy had a median cryocrit at diagnosis of 10% (n 5 50, range 0 to 96), significantly higher than median cryocrit of 5% in patients with MGUS (n 5 24, range 0 to 83); P 5 .01. The median cryocrit in seven patients without a lymphoproliferative disorder was 0.001 (range 0 to 9). At start of treatment, the median cryocrit was 10% in the 46 patients where data was available. The median nadir cryocrit on treatment was 0% (n 5 33). Median change in cryocrit was 8% in patients with hematologic malignancy (n 5 22) and 1% in patients with MGUS (n 5 7), though this difference was not statistically significant (P 5 .44). (Table 3 ).
| Symptom burden improvement
Of the 73 patients who received treatment, 47 (64%) showed symptomatic improvement with first-line therapy, while symptoms remained stable in 16 (22%). Progression of symptoms was observed in three patients (4%) and (7%) were asymptomatic at initiation of treatment.
The outcome was unknown in two patients. Symptom improvement with specific treatment regimens are listed in 
| Outcomes with treatment in specific hematologic disorders
Alkylating agents in combination with steroids were given to 11 of 39 patients (28%) with MGUS followed by steroids (n 5 5, 13%) and rituximab based treatment (n 5 5, 13%). Majority of patients showed improvement in symptoms (nine of eleven treated with alkylating agents and four out of five in both the steroid and rituximab group).
Observation or conservative measures were employed in eight patients. Improvement in symptoms with treatment was seen in 57% improvement in symptoms in four out of five patients Six patients also received high dose chemotherapy followed by ASCT. In four of these patients, treatment was directed toward cryoglobulinemia-related symptoms, including three patients with smoldering myeloma and one patient with both amyloidosis and myeloma. In the other two patients, ASCT was performed for the associated multiple myeloma. In subjects with underlying lymphoplasmacytic lymphoma, rituximab based therapies were used in 12 of 21 (57%), and in half of these patients alkylating agents were combined with rituximab (n 5 6). Improvement in symptoms was seen in three of 12 patients, while six remained stable and three were asymptomatic when therapy was started. In terms of objective disease response, two of the six patients treated with rituximab with or without steroids had stable disease, one had a minor response, one progressed and in two patients response was not evaluable. In the six patients who were treated with alkylating agents and rituximab, fifty percent had an objective response (very good partial response 5 1, partial response 5 2), while disease remained stable in two patients and was not evaluable in one patient. Novel agents were used less commonly and in the two patients who were treated, one patient had symptomatic improvement and the other did not have cryoglobulinemia-related symptoms prior to treatment. Both of these patients had an objective partial response. Additional treatment details for specific disorders are available in Supporting Information.
| Survival
At last follow-up, 78 (77%) patients were alive as depicted in Figure 1a with median survival of the cohort being 11.4 years (95% CI: 7.1, not reached). Patients who did not have neurologic symptoms had a better survival outcome compared to those with neurologic symptoms at presentation (median survival 14.7 years vs. 7.1 years; Log-Rank P 5 .0048) as shown in Figure 1b . There was a trend toward better survival for patients with MGUS compared to hematologic malignancies, but this was not statistically significant (P 5 .08). (Figure 1c ) Older age was also predictive of poorer survival outcomes (P 5 .0001). Other factors including presence of other symptoms or specific organ involvement (for example kidney involvement (P 5 .99), cryocrit at diagnosis (P 5 .5), change in cryocrit over time (P 5 .48) and nadir cryocrit (P 5 .73) were not found to be significant in a univariate analysis.
Therefore, a multivariate analysis has not been shown.
| DISCUSSION
Our study is the largest reported series of patients with Type 1 MoC to the best of our knowledge and patients with Type 1 MoC represented 22% of all patients with cryoglobulinemia, consistent with prior reports. 1, 3, 10, 11 Most patients in our series were symptomatic, which is similar to a prior report. 3 These results differ from another study, where only 16% patients had symptoms. 4 It is not routine clinical practice at our institution to check cryoglobulins in asymptomatic patients and this likely explains the difference in our findings. Distribution of symptoms in our study is consistent with prior reports; skin involvement with vasculitic purpura was the most common symptom followed by neurological manifestations, specifically peripheral neuropathy. [1] [2] [3] [4] Most patients with renal involvement had glomerulonephritis on biopsy, with one patient having thrombotic microangiopathy and although rare, it has been reported in the past. 4 Atypical manifestations in our series included rhino-sinusitis and recurrent epistaxis. These findings are not characteristic, but are likely secondary to precipitation of cryoglobulins in the naso-turbinal circulation on exposure to cold air. Similar cases have been reported. 12 Unusual symptoms included worsening of MGUS-related xanthomas on exposure to cold in one patient. This phenomenon is uncommon, but has been described in two patients with xanthomas related to monoclonal gammopathies, and one of these patients had a type 1 cryoglobulin. 13 Recurrent angioedema was seen in one patient, and although rare, it has also been reported and is proposed to occur due to complement activation by cryoglobulins, leading to consumption of C1 inhibitor resulting in acquired C1 esterase deficiency. 14 The distribution of underlying lymphoproliferative disorder in our series is consistent with prior results, with MGUS being the most common followed by multiple myeloma and Waldenstr€ om's macroglobulinemia. [2] [3] [4] Interestingly, hepatitis C was the underlying [2] [3] [4] No difference in survival or symptom improvement was noted in patients who received plasmapheresis compared to those who did not. However, it is difficult to draw any conclusions given the small numbers and the fact that patients who received plasmapheresis likely had a more severe clinical presentation. Autologous stem cell transplantation primarily for management of cryoglobulinemia-related symptoms, though rare, has been utilized at other centers as well in a few cases. 3 In general, treatment should be directed at the underlying lymphoproliferative disorder and intensity of treatment, including decision to pursue plasmapheresis should be determined by severity of symptoms related to the cryoglobulin. 15 For patients with non-IgM MGUS and multiple myeloma, novel myeloma directed therapy should be considered; while rituximab-alkylator based therapy may be more appropriate for patients with IgM MGUS and Waldenstr€ om's macroglobulinemia.
It has been previously reported that nephropathy and presence of hematologic malignancy compared to MGUS is associated with a poor survival, although these findings have not been consistent across different series. [2] [3] [4] Survival outcomes were worse in patients with neurological symptoms at presentation in our cohort and a trend toward better survival with MGUS compared to hematologic malignancies.
Limitations of our study include its retrospective design; heterogeneity of treatment regimens and limitations of follow up. We also cannot accurately estimate the percentage of patients who are symptomatic from the presence of a Type 1 cryoglobulin as we do not routinely screen patients for cryoglobulinemia. We have not captured the severity of presentation or degree of improvement to avoid bias given retrospective nature of our study. Despite limitations, our study provides valuable insights into this rare disorder.
In conclusion, most patients with type 1 monoclonal cryoglobulinemia have an underlying clonal hematologic disorder with various symptoms attributable to precipitation of cryoglobulins. Treatment directed at the underlying lymphoproliferative disorder results in improvement or stabilization of symptoms in the majority of patients, with disappearance in cryoglobulin in over half the cases.
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